The FDA approved Dec. 5 three applications for the first generic versions of Gilenya, Novartis’ drug designed to treat adults with relapsing forms of multiple sclerosis. The approvals were granted to ...
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec is certainly hoping so. The biotech's multiple sclerosis drug Tecfidera received a positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback